You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

ATACAND Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Atacand patents expire, and what generic alternatives are available?

Atacand is a drug marketed by Ani Pharms and is included in two NDAs.

The generic ingredient in ATACAND is candesartan cilexetil; hydrochlorothiazide. There are twenty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the candesartan cilexetil; hydrochlorothiazide profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ATACAND?
  • What are the global sales for ATACAND?
  • What is Average Wholesale Price for ATACAND?
Summary for ATACAND
Drug patent expirations by year for ATACAND
Drug Prices for ATACAND

See drug prices for ATACAND

Recent Clinical Trials for ATACAND

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The University of Texas Health Science Center, HoustonEarly Phase 1
AgoneX Biopharmaceuticals, Inc.Phase 2
BioHealthonomics Inc.Phase 2

See all ATACAND clinical trials

Pharmacology for ATACAND
Paragraph IV (Patent) Challenges for ATACAND
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ATACAND Tablets candesartan cilexetil 4 mg, 8 mg, 16 mg and 32 mg 020838 1 2006-12-22

US Patents and Regulatory Information for ATACAND

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ani Pharms ATACAND candesartan cilexetil TABLET;ORAL 020838-001 Jun 4, 1998 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ani Pharms ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093-003 May 16, 2008 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ani Pharms ATACAND candesartan cilexetil TABLET;ORAL 020838-004 Jun 4, 1998 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ani Pharms ATACAND candesartan cilexetil TABLET;ORAL 020838-002 Jun 4, 1998 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ani Pharms ATACAND candesartan cilexetil TABLET;ORAL 020838-003 Jun 4, 1998 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ani Pharms ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093-002 Sep 5, 2000 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ani Pharms ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093-001 Sep 5, 2000 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ATACAND

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ani Pharms ATACAND candesartan cilexetil TABLET;ORAL 020838-003 Jun 4, 1998 ⤷  Sign Up ⤷  Sign Up
Ani Pharms ATACAND candesartan cilexetil TABLET;ORAL 020838-003 Jun 4, 1998 ⤷  Sign Up ⤷  Sign Up
Ani Pharms ATACAND candesartan cilexetil TABLET;ORAL 020838-002 Jun 4, 1998 ⤷  Sign Up ⤷  Sign Up
Ani Pharms ATACAND candesartan cilexetil TABLET;ORAL 020838-001 Jun 4, 1998 ⤷  Sign Up ⤷  Sign Up
Ani Pharms ATACAND candesartan cilexetil TABLET;ORAL 020838-004 Jun 4, 1998 ⤷  Sign Up ⤷  Sign Up
Ani Pharms ATACAND candesartan cilexetil TABLET;ORAL 020838-001 Jun 4, 1998 ⤷  Sign Up ⤷  Sign Up
Ani Pharms ATACAND candesartan cilexetil TABLET;ORAL 020838-001 Jun 4, 1998 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ATACAND

See the table below for patents covering ATACAND around the world.

Country Patent Number Title Estimated Expiration
Norway 924417 ⤷  Sign Up
Hungary 211608 ⤷  Sign Up
Portugal 97451 PROCESSO PARA A PREPARACAO DE DERIVADOS DE BENZIMIDAZOLE E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM ⤷  Sign Up
Finland 20012172 ⤷  Sign Up
China 1147515 ⤷  Sign Up
Japan 2682353 ⤷  Sign Up
Austria 157248 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ATACAND

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0459136 SPC/GB97/018 United Kingdom ⤷  Sign Up PRODUCT NAME: CANDESARTAN CILEXETIL OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK PL0017/0383 19970429; UK PL0017/0384 19970429; UK PL0017/0385 19970429; UK PL0017/0391 19970429; UK PL15561/0003 19970429; UK PL15661/0001 19970429; UK PL15661/0002 19970429; UK PL15661/0004 19970429
0459136 SZ 8/1998 Austria ⤷  Sign Up
0459136 98C0016 Belgium ⤷  Sign Up PRODUCT NAME: CANDESARTAN CILEXETIL; NAT. REGISTRATION NO/DATE: 212 IS 236 F3 19980119; FIRST REGISTRATION: GB PL 15661/0001 19970429
0459136 8/1998 Austria ⤷  Sign Up PRODUCT NAME: CANDESARTAN CILEXETIL ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; NAT. REGISTRATION NO/DATE: 1-22232, 1-22233, 1-22235, 1-22236 19971119; FIRST REGISTRATION: GB PL 15661/0001 - PL 15661/0004 19970429
0459136 19875004 Germany ⤷  Sign Up PRODUCT NAME: WIRKSTOFF DES ARZNEIMITTELS BLOPRESS BZW. DES ARZNEIMITTELS ATACAND IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; NAT. REGISTRATION NO/DATE: 41261.00.00 41261.01.00 41261.02.00 41261.03.00 41294.00.00 41294.01.00 41294.02.00 41294.03.00 19971203 FIRST REGISTRATION: GROSSBRITANNIEN 15661/0001 15661/0002 15661/0003 15661/0004 19970429
0459136 C970044 Netherlands ⤷  Sign Up PRODUCT NAME: CANDESARTAN, DESGENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF VAN DE 1-(CYCLOHEXYLOXYCARBONYLOXY) ETHYLESTE R, IN HET BIJZONDER CILEXETILI CANDESARTANAS, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: RVG 21703 - RVG 21706 19971013; FIRST REGISTRATION: GB PL 15661/0001 - PL 15661/0004 19970429
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.